Henan Huashang Pharmaceutical Co., Ltd.

Henan Huashang Pharmaceutical Co., Ltd. Founded in 2004. is situated in Zhecheng Economic Development Zone, Shangqiu City, Henan Province. As a national high-tech enterprise, the company specializes in the R&D, production, and sales of pharmaceutical active pharmaceutical ingredients (APIs) and fine pharmaceutical intermediates. With a total investment of RMB 160 million, the company occupies a site area of approximately 100,000 m² and currently employs over 170 staff members. It has established a comprehensive system integrating R&D, manufacturing, quality control, and marketing. The company’s core business focuses on sartan-series APIs and intermediates, as well as loxoprofen sodium intermediates. Its flagship products include key intermediates for candesartan cilexetil, telmisartan, irbesartan, and loxoprofen sodium. Thanks to consistent product quality and large-scale production capacity, Huashang has become a leading domestic supplier of sartan and loxoprofen sodium intermediates. Its products are exported to numerous countries and regions across North and South America, Europe, Southeast Asia, and beyond. Backed by strong R&D and regulatory compliance capabilities, the company has successfully obtained the drug registration approval for telmisartan API (Registration No.: Y20240001019) and passed the GMP on-site inspection in April 2026. Huashang has been honored as a National Green Factory and a Model Enterprise for Energy-Saving & Technological Innovation in Henan Province. It holds three major international system certifications: ISO9001 (Quality Management), ISO14001 (Environmental Management), and ISO45001 (Occupational Health and Safety Management). Adhering to the principles of compliant production, green development, and quality-first operation, the company remains deeply committed to the API and intermediate sector, striving to build a world-class, high-standard R&D and manufacturing base for pharmaceutical ingredients.